{"id":"NCT05074888","sponsor":"Materia Medica Holding","briefTitle":"Ð¡linical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.","officialTitle":"A Multicenter, Double-blind, Placebo-controlled, Parallel-group, Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Patients With Post-COVID-19 Asthenia.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-15","primaryCompletion":"2022-06-08","completion":"2022-06-08","firstPosted":"2021-10-12","resultsPosted":"2024-09-23","lastUpdate":"2024-09-23"},"enrollment":676,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Post-acute COVID-19 Syndrome"],"interventions":[{"type":"DRUG","name":"Prospekta","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Prospekta","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial.\n\nThe objective of this study is to evaluate the efficacy and safety of Prospekta in the treatment of asthenia in patients after the coronavirus infectious disease (COVID-19).","primaryOutcome":{"measure":"Change in the Mean FSS Score.","timeFrame":"after 4 weeks of treatment","effectByArm":[{"arm":"Prospekta","deltaMin":46.4,"sd":6.9},{"arm":"Placebo","deltaMin":45.9,"sd":6.6}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0016"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":32,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":330},"commonTop":["Headache","Dizziness","Viral infection of the respiratory tract","Laboratory confirmed coronavirus infection COVID-19","BP above normal"]}}